Bladder cancers are biologically and clinically heterogeneous. Recent large-scale transcriptomic profiling studies focusing on life-threatening muscle-invasive cases have demonstrated a small number of molecularly distinct clusters that largely explain their heterogeneity. Similar to breast cancer, these clusters reflect intrinsic urothelial cell-type differentiation programs, including those with luminal and basal cell characteristics. Also like breast cancer, each cell-based subtype demonstrates a distinct profile with regard to its prognosis and its expression of therapeutic targets. Indeed, a number of studies suggest subtype-specific differential responses to cytotoxic chemotherapy and to therapies that inhibit a number of targets, including growth factors (EGFR, ERBB2, FGFR) and immune checkpoint (PD1, PDL1) inhibitors. Despite burgeoning evidence for important clinical implications, subtyping has yet to enter into routine clinical practice. Here we review the conceptual basis for intrinsic cell subtyping in muscle-invasive bladder cancer and discuss evidence behind proposed clinical uses for subtyping as a prognostic or predictive test. In deliberating barriers to clinical implementation, we review pitfalls associated with transcriptomic profiling and illustrate a simple immunohistochemistry (IHC)-based subtyping algorithm that may serve as a faster, less expensive alternative. Envisioned as a research tool that can easily be translated into routine pathology workflow, IHC-based profiling has the potential to more rapidly establish the utility (or lack thereof) of cell type profiling in clinical practice.
Introduction
Urothelial carcinoma (UC) derives from specialized epithelia lining the bladder wall. Using a well-established differentiation program, basal stem cells at the stromal interface self-renew and generate intermediate and superficial/umbrella cells to maintain and regenerate normal urothelium as needed. Most urothelial cancers do not have the ability to invade into the submucosal stroma (lamina propria) or bladder wall (muscularis propria), but those that do can display remarkable diversity in histologic variants, clinical outcomes, and molecular profiles. Prediction of response to available peri-operative treatment, and the development of novel means of targeting invasive bladder cancers, are areas of intense research, where molecular profiling is postulated to be of value. Molecular analysis of the diagnostic trans-urethral resection of bladder tumor (TURB-T) specimens represents an optimal approach to understanding bladder tumor biology, and the availability of such samples prior to radical surgery allows molecular profiling to potentially inform patient decisions related to both surgery and neoadjuvant treatment. As discussed below, the differentiation programs and molecular subtypes that operate in invasive bladder tumors relate back to the differentiation states of the urothelium, but they also relate forward to pan-cancer cellular and stromal phenotypes. Thus, molecular subtypes serve as a context that links the biology of tumor development to the potential to influence and stratify patients to improve oncological outcomes. We limit this review to describe the state of molecular profiling in564 G Sjödahl et al a relatively understudied topic. With more studies on non-muscle-invasive bladder cancer on the horizon, patient stratification for intravesical therapy will be a pressing unresolved issue. The target audience for this review is twofold. For the healthcare professional who diagnoses or treats bladder cancer, we aim to provide a logical structure of molecular subtypes, an enumeration of promising targeted therapies, and a vision of how molecular subtypes could be implemented in routine pathology. We also aim to provide basic researchers in molecular pathology with an up-to-date view on current biomarkers, and insights into the complex interpretation of molecular subtypes in tissue samples with the cellular diversity of invasive bladder cancers. To provide clinical and historical context, we also very briefly review the current treatment for the superficial, invasive, and metastatic stages of bladder cancer, and the two major pathways of tumor development.
Stages of urothelial carcinoma

Non-muscle-invasive
Urologists typically use the term 'superficial' or 'non-muscle-invasive' bladder cancers (NMIBCs) to describe non-invasive UCs and their minimally invasive counterparts that extend only into the lamina propria. Superficial cases constitute more than 75% of incident bladder cancer cases. Uncommonly, they present as pure flat carcinoma in situ (CIS), which carries a high risk of progression. Most often, they present as non-invasive papillary UC, which carries a high risk of recurrence but a relatively low risk of progression to life-threatening muscle-invasive (MIBC) disease [1] [2] [3] . For high-risk NMIBC, intravesical instillations of bacillus Calmette-Guérin (BCG) effectively reduce the risk for progression by stimulating an anti-tumor immune response [4] . Adverse prognostic factors in NMIBC include high pathological grade, large tumor size, multifocality, and the presence of CIS [1, 3] .
Muscle-invasive
Approximately 15% of non-muscle-invasive cases evolve into more aggressive and invasive forms that extend into the muscular bladder wall, an event that appears to be required for bladder cancer to acquire a lethal phenotype. Bladder cancer is more frequent in men, and in more developed countries, but local variation occurs, e.g. due to the high prevalence of schistosomiasis in parts of Africa [5] . As specified in clinical guidelines, definitive management of localized MIBC centres on cystectomy and peri-operative platinum-based chemotherapy regimens. However, the application of these guidelines and treatment outcomes vary widely, from patient to patient and from caregiver to caregiver [6, 7] . Despite high-level evidence, pre-operative neoadjuvant chemotherapy (NACT) is not widely utilized [8, 9] . Adjuvant chemotherapy (ACT), in contrast, is more frequently employed, despite relatively weaker evidence of benefit [10] .
Metastatic
Despite best efforts at local control, more than 50% of patients with MIBC experience and ultimately die of distant metastases. Furthermore, 18-25% of cystectomy patients with muscle-invasive bladder cancer already have metastatic disease at the time of surgery [11] . Thus, there is a sizeable proportion of patients with urgent need for effective systemic therapy. As in the peri-operative setting, guidelines recommend cisplatin-based combination chemotherapy for fit patients with metastatic bladder cancer, although only approximately 15% of patients will achieve long-term survival greater than 2 years. Beyond chemotherapy, recent modest successes in immunotherapy trials with checkpoint inhibitors represent the first significant improvements in treating metastatic UC in decades [12] .
In clinical practice, prognosis and treatment decisions are driven by histopathologic evaluation of stage and grade as well as clinical features including adverse imaging findings. There are currently no molecular classification strategies in routine use for UC patients, but biomarker discovery research in chemotherapy, immunotherapy, and targeted therapy trials is ongoing. Early results suggest that molecular profiling will be useful for patient stratification, as discussed below.
This optimism stems, in part, from other cancer types, where expression, mutation, and/or activation of drug targets (e.g. EGFR mutations) in the patient's tumor is used to guide treatment and monitor resistance mechanisms (e.g. KRAS mutations). This molecular information can be paired with information about tumor subtype, which may provide additional evidence of benefit. While profiling and classification of NMIBC have been slow, recent studies in MIBC have yielded a treasure trove of information regarding genomic and transcriptomic subtypes. Consensus between classification schemes has gradually emerged and excitement is building around implementing these discoveries to benefit patients. Yet significant challenges remain, particularly with regard to devising a clinically relevant, biologically valid, and practical rubric for testing patients. Recent work [13, 14] has highlighted pitfalls in transcriptomic profiling and the importance of immunohistochemistry (IHC) assays for reconciling how cancer cell-specific gene expression relates to RNA-based clustering approaches. Here, we review the basis, performance, and clinical relevance of molecular classification of muscle-invasive UC. We compare and contrast transcriptomic-and IHC-based profiling, and explore the potential for implementing these tools in routine clinical practice.
Intrinsic subtypes of bladder cancer 565 of papillary UCs from their flat counterparts [15] [16] [17] . Papillary carcinomas are distinguished by branching structures that extend into the bladder lumen. At the molecular level, papillary cancers are enriched for activating mutations in the fibroblast growth factor receptor 3 (FGFR3) oncogene [18, 19] , whereas cancers that develop through the flat carcinoma in situ pathway lack FGFR3 mutations and are instead enriched for inactivating mutations in the TP53 and retinoblastoma (RB1) tumor suppressor genes [17] . Intriguingly, the minority of papillary UCs that do progress to MIBC show genomic instability and a propensity for homozygous loss of CDKN2A [20, 21] , which may serve as an alternate means to disable TP53 and RB1. The two tumor suppressor proteins p16INK4a and p14ARF encoded by CDKN2A regulate functions of RB and TP53, and thus encapsulate a wide range of tumor suppressor function in one genomic event.
In 2009, two laboratories investigating cancer stem cells discovered that, much like stem cells in benign urothelium, bladder cancer stem cells localize to the basal compartment at the stromal interface [22, 23] . These cells sustain long-term tumor growth and exhibit mRNA expression profiles that are distinct from their more differentiated, less tumorigenic progeny. Importantly, these studies also showed that a shift toward basal cell gene signatures is associated with higher stage and decreased survival. The importance of basal cell differentiation in bladder cancer as an indicator of poor prognosis was soon confirmed in larger-scale profiling studies [24] [25] [26] [27] [28] [29] [30] .
The use of unsupervised clustering to discover basal and luminal UC subtypes echoes seminal work by Perou et al [31] and Sørlie et al [32] , who identified intrinsic basal and luminal profiles for breast cancer, with poor and initially good outcomes, respectively. Luminal breast cancers, however, exhibit later relapses and lethality. Importantly, intrinsic breast cancer subtypes resonated with scientists and clinicians because they mapped well to an existing paradigm of treatment, which differs between ER-positive (luminal) and ER-negative (including basal-like cancers) cancers [33] . However, clinical profiling in breast cancer currently focuses less on molecular subtyping and more on predictive biomarkers such as ER, progesterone receptor, and ERBB2 (a.k.a. HER2) and on residual risk of disease relapse and progression. Thus, RNA-based subtyping has not become mandatory in diagnostic or routine clinical use. It has, however, proven scientifically invaluable and useful for bridging biological and clinical lexicons. For this reason, there was considerable fanfare when, a decade later, analogous subtypes were discovered in UC.
Gene expression signatures in the molecular subtypes of MIBC
Since a small number of relevant studies [25, 34, 35] indicate that nearly all NMIBC tumors are luminal-like, we will not discuss them further except to state that the precise frequency by which molecular subtypes occur in different pathological stages of bladder cancer remains unclear.
The following description of gene expression signatures and their relationship with molecular subtype classification will be based on the data and conclusions of the main studies on MIBC [25] [26] [27] [28] [29] [30] 36] . The different MIBC classification systems are largely overlapping [37] and operate at different levels in a hierarchical structure [38] . Here, we briefly describe the biological characteristics that shape the hierarchy of bladder cancer molecular subtypes.
Luminal-like MIBC
At the top hierarchical level, bladder tumors can be divided into luminal-like and non-luminal-like classes based on the presence or absence of a bimodally expressed urothelial differentiation signature. About half of MIBCs express this signature, which includes KRT20, UPK1-3, transcriptional regulators, e.g. PPARG, GRHL2-3, ELF3, TBX2-3, and pioneer factors GATA3 and FOXA1. While many studies have grouped luminal-like tumors together, The Cancer Genome Atlas (TCGA) Consortium and a group in Lund, Sweden have subdivided this class of MIBCs further. The Lund classification introduces two such sub-classes termed 'urothelial-like' (Uro) and 'genomically unstable' (GU), which differ in prognosis, and tumor-cell intrinsic genomic properties which, respectively, include loss of CDKN2A versus RB1, alterations of FGFR3 versus ERBB2, and maintained versus defective cell-cell adhesion. Most importantly, immunohistochemical studies [39] have shown that only the Uro subtype retains stratification of a basal cell-layer, wherein stem cells had previously been shown to reside [22, 23] . In contrast, tumors of the GU subtype, while expressing the urothelial-differentiation gene signature, are in fact poorly differentiated, lack cell polarity, and are uniformly negative for basal-cell markers [40] . The TCGA Consortium introduced another three-tier sub-classification of luminal-like tumors: 'luminal-papillary' (Lum-Pap), 'luminal-infiltrated' (Lum-Inf), and 'luminal' (Lum) [29] . The separation between the TCGA sub-classes differs from that of the Lund group in that it is driven by relatively high levels of immune-and stroma-related genes in the Lum-Inf and Lum sub-classes, respectively, whereas Lum-Pap tumors are low in both stromal and immune transcripts.
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and immune-related transcripts and is further characterized by squamous differentiation, and expression of genes, e.g. S100A7, SPRR1B, and SPRR3, located in the epidermal differentiation complex on chromosome 1q21 [41] . These genes govern the differentiation and function of squamous epithelia and are not expressed in urothelial basal cells, which is why the dual-label 'basal/squamous' (Ba/Sq) is preferred. The similarity between this subtype and benign basal urothelial cells is limited to positive expression of a handful of markers, but unlike the Ba/Sq subtype, normal basal cells retain expression of urothelial differentiation factors, e.g. PPARG and GATA3. Further support for the squamous rather than the basal-like nature of this subtype is lent by its stronger similarity in integrative pan-cancer studies with squamous cell carcinomas of the head and neck or lung than with other bladder cancers or basal-like breast cancer [42] .
In addition, several independent groups have identified additional tumors that are neither luminal-like nor Ba/Sq. Kardos et al [43] have described a 'claudin-low' subset of advanced urothelial carcinomas with such a profile, and Dadhania et al [13] described a 'double-negative' subtype, simultaneously lacking both urothelial and squamous differentiation markers. Classification according to both Lund and TCGA has identified a subtype with strong neuroendocrine features that is enriched for cases with small-cell or neuroendocrine variant histology [14, 29] . The Lund group has also described a mesenchymal-like subtype in which expression of epithelial cell adhesion molecules CDH1 and EPCAM is replaced by mesenchymal markers VIM and ZEB2 [14] . Both neuroendocrine-like and mesenchymal-like MIBCs also fit the bill as 'double negative' and 'claudin-low.' Thus, these subtypes may encompass rare entities that are not luminal-like, but are clearly distinct from the Ba/Sq subtype. The frequency and exact subdivision of these minor subtypes in a study cohort may depend on inclusion criteria for non-UC variant histology. As with histologic variants, powering clinical trials to link these minor subtypes to clinical outcome may prove challenging, and the utility of further sub-classifying non-luminal, non-basal subtypes remains to be proven.
Therapeutic opportunities for molecular profiling in muscle-invasive urothelial carcinoma
Recently published data from the TCGA Consortium reported that 69% of bladder cancers contain potentially actionable therapeutic targets, which associate with specific molecular subtypes [29] . In this section, summarized in Figure 1 , we describe current efforts towards using molecular profiling as a patient stratification method for clinical trials and ultimately clinical practice.
Peri-operative cytotoxic chemotherapy
The gold-standard management for MIBC patients with disease confined to the pelvis includes radical cystectomy preceded by platinum-based neoadjuvant chemotherapy (NACT). Indeed, a significant minority of patients treated this way achieve durable responses and increased cancer-specific survival [44] . However, a meta-analysis has suggested a marginal absolute survival benefit for NACT of only 5% at 5 years [45] . The marginal benefit is further diminished by concerns regarding delayed surgery, the non-selective nature of treating all MIBC patients with NACT, and its risk of serious morbidity. Thus, although trending upward, reported utilization rates of NACT for cystectomy patients rarely exceed 25% [46] [47] [48] .
Biomarker tests that predict chemoresponse could address these problems by identifying patients most likely to benefit. Recent efforts have explored the potential utility of RNA-based subtype classifiers to serve as biomarkers of NACT response [36, 37, 49] . Intriguingly, two retrospective studies indicate that NACT may preferentially benefit patients with basal-like subtypes [36, 49] . Unlike historical untreated controls who show better survival with luminal subtypes, NACT-treated patients in these studies showed superior survival rates in basal-like cancers, although the survival benefit was not reflected in the proportions achieving pathological downstaging. Overall, data to date provide support Intrinsic subtypes of bladder cancer 567 for prospective clinical trials to confirm the utility of subtyping in choosing patients for NACT. Since the biologic basis of response to chemotherapy could be similar in the peri-operative (neoadjuvant and adjuvant) setting and at progression to metastatic disease, additional studies should explore applications of cell-based subtyping at later stages in cancer progression.
FGFR3
Mutations, gene fusions, and amplification of the gene encoding fibroblast growth factor receptor 3 (FGFR3) are present in approximately 50-80% of superficial bladder cancers and up to 20% of muscle-invasive bladder cancers [29, 50, 51] . Early phase clinical trials of FGFR inhibitors such as BGJ398 and erdafitinib have reported activity in metastatic post-platinum UC patients [52] [53] [54] . Despite high rates of FGFR3 mutation in luminal-papillary tumors, clinical trials have not incorporated molecular subtyping strategies to determine patient eligibility. Interestingly, there may be an inverse relationship between immunotherapy response and presumed features of FGFR3 inhibitor response, since response to atezolizumab was low in the TCGA 'cluster 1' luminal subtype that includes most FGFR3 alterations [55] . Indeed, a preliminary subgroup analysis of the erdafitinib study showed a 70% confirmed overall response rate among patients who previously failed immune checkpoint inhibitors [54] . If confirmed, these relationships between response and subtype suggest that cell-based subtyping will be an efficient means of stratifying patients for treatments and, at least in some instances, decrease the need for more complex molecular testing.
ERBB2/HER2
Activating mutations in ERBB2 (also known as HER2) have been found in approximately 12% of MIBC cases, with basal-squamous subtypes showing about half the rate of alterations (6%) compared with other subtypes (12-15%) [29] . Genomic amplification of HER2 is common and increases the number of potentially targetable cases to over 20% [56, 57] . However, response to anti-HER2 therapies have largely yielded negative results in muscle-invasive bladder cancer [58] [59] [60] . A clinical trial conducted with lapatinib, a dual tyrosine kinase inhibitor for EGFR and ERBB2, saw no improvement in progression-free survival for 232 HER2
+ patients with metastatic UC [60] . Other therapeutic approaches for HER2 + bladder cancer patients include a phase 2 trial of DN24-02, a cellular immunotherapy with HER2-derived antigen linked to granulocyte macrophage colony-stimulating factor, but no significant differences in overall survival or distant recurrence-free survival were observed [59] . These poor historical response rates to HER2 inhibitors may be a function of the requirement for HER2 receptor heterodimerization with other members of the EGFR receptor family for signaling. Indeed, both the EGFR and the ERBB3 receptors also show subtype-specific overexpression; ERBB3, like HER2, is highest in luminal-like (Uro and, particularly, GU luminal-like subtypes), whereas EGFR is highest in basal-squamous subtypes [41, 57] .
RXR-α and PPAR-γ
The retinoid X receptor alpha (RXR-α) and peroxisome proliferator-activated receptor gamma (PPAR-γ) are central for urothelial differentiation [61] . Genetic alterations in RXRA and PPARG have been reported in up to 40% of MIBC patients [29] , supporting a role in bladder carcinogenesis. Furthermore, some studies have shown associations between the use of pioglitazone, a PPAR-γ agonist used in treating diabetes, and an increased risk of bladder cancer [62] . Functionally, RXR-α heterodimerizes with PPARs, activating transcription of PPAR-regulated genes involved in fatty acid metabolism [63] . Hotspot mutations in the ligand binding domain of RXR-α (S427F/Y) are enriched in bladder cancers and have been shown to stabilize the heterodimerization between RXR-α and PPAR-γ, enhancing its interaction with co-activators and initiating downstream transcriptional regulation [63, 64] . Expressing RXR-α S427F in a syngeneic mouse bladder tumor model activated the PPAR-γ pathway, reduced levels of tumor-infiltrating CD8 + T cells, and blunted the effects of anti-CTLA4 immunotherapy treatments [64] . Conversely, patients whose cancers show a high density of T cells have shown better anti-tumor immunity in clinical trials of immune checkpoint inhibitors targeting CTLA-4 and PD-1 [65] . Both RXRA mutations and 3p25 amplifications spanning PPARG are significantly enriched in the luminal-like subtypes [29] . Therefore, investigators have proposed that antagonizing PPAR-γ/RXR-α may sensitize bladder cancers to immunotherapies, especially for non-inflamed subsets that may have an inferior response to immunotherapies [55, 64] . If further evidence supports this proposal, PPAR-γ may become a target for predictive biomarkers and therapeutic intervention, particularly in luminal subtypes of MIBC.
PD1/PD-L1 immune checkpoint inhibitors
Tumor cells evade the immune system by expressing immunosuppressive signals that block active engagement of cytotoxic, tumor-killing T cells. Immune checkpoint inhibitors in current clinical use for MIBC include atezolizumab and nivolumab, which target signaling by programmed death-ligand 1 (PD-L1) on tumor cells to its cognate receptor, programmed death-1 (PD1) on activated T cells [65] . UC has shown dramatic, sometimes durable, responses to these agents [66] , even in chemotherapy-refractory metastatic disease [67] [68] [69] . However, checkpoint inhibitors are not universally effective and come at an extraordinary financial cost, supporting the need for predictive biomarkers. Factors such as PD-L1 expression and tumor mutational burden have been investigated as predictive biomarkers for response to PD1/PDL-1-based immunotherapies, with limited success [65, 68, 69] . More recent efforts have investigated the potential of cell-based molecular subtypes as effective predictive biomarkers. The IMvigor210 phase 2 clinical trial tested patients who progressed after platinum-based chemotherapy for responses to atezolizumab and potential relationships with molecular subtypes as defined by the TCGA clusters I-IV. Patients with immune infiltrated luminal (cluster II) and basal (cluster IV) tumor subtypes showed the highest objective response rates (34% and 20%, respectively, compared with 10% and 16% for the non-infiltrated clusters I and III) [55] . Similarly, in cisplatin-ineligible patients, atezolizumab showed the greatest benefit in patients with the immune infiltrated luminal II subtype [66] . The phase 2 CheckMate275 clinical trial tested nivolumab as a second-line therapy in metastatic urothelial carcinoma patients. The trial demonstrated notable improvements in response associated with the basal I and luminal II subtypes, with partial or complete responses in 30% and 27% of patients, respectively, in comparison to the 19% overall response rate [67] . Overall, the success of PD1 and PD-L1 inhibitors in non-tumor-cell intrinsic subtypes (Table 1) suggests that the efficacy of these immunotherapies may be related to the tumor microenvironment (TME) type, rather than the tumor cell phenotype. Therefore, reliable relationships have yet to be established between checkpoint inhibitor response and urothelial carcinoma phenotypes and genotypes.
Hedgehog and bone morphogenetic proteins
As shown in model systems, signaling between tumor and stroma can promote or restrain cancer progression [70] [71] [72] . For example, in mice, sonic hedgehog (Shh) expression from epithelial cells activates expression of bone morphogenetic protein (Bmp) in the subjacent stroma, which then feeds back upon epithelial cells to maintain differentiation of the urothelium [71, 72] . Engineered ablation of Shh signaling in murine urothelium downregulates Bmp signaling and accelerates bladder cancer growth and invasion [72] , a process that was inhibited by administration of tacrolimus (FK506). Tacrolimus is best known as an immunosuppressive agent for organ transplant patients that suppresses cytokine expression. The drug appears to also stimulate activation of BMP receptors, which was shown to be required for suppressing UC progression [72] . If these results are tested and confirmed in humans, they may be more applicable to patients with basal/squamous subtype cancers, as these show the lowest expression of SHH and BMP7 genes [29, 38] .
TGFβ
Transforming growth factor beta (TGFB) signals through canonical and non-canonical pathways. Through SMADs, it can activate PI3K-AKT, RHOA, and MAPK pathways [73, 74] . TGFβ signaling appears to exclude tumor-killing T cells from UCs and serves as a reversible mechanism of resistance to PDL1 targeted immunotherapy. Mariathasan et al [70] reported a CD8 + T-cell effector phenotype associated with response to atezolizumab in patients with metastatic urothelial carcinoma. Strikingly, tumors from non-responders showed immune cell exclusion, and instead were enriched for a signature indicating TGFβ signaling in fibroblasts. In a mouse model of breast cancer, addition of TGFβ-neutralizing antibodies to PD-L1 blockade resulted in increased cytotoxic T-cell infiltration into tumors and more effective anti-tumor immune responses [70] , providing functional evidence that stromal TGFβ could be an important arbiter of immune response. Importantly, the same study also reported significantly different rates of response to atezolizumab depending on the Lund molecular subtype, with highest response rates in the genomically unstable and lowest in the UroA subtype. As with response to checkpoint inhibitors, the potential utility of modulating TGFβ is perhaps more closely linked to the TME type than to the cancer cell subtype.
Considerations of cell type and sampling in MIBC molecular subtype classification
Transcript-based biopsy profiling and in situ cell profiling (i.e. IHC) are two fundamentally different methods for profiling gene expression in tumors. Several publications provide evidence that the mRNA-based subtypes discussed above correspond to in situ tumor cell intrinsic immunophenotypes. Luminal-like and basal-like gene expression subtypes were reliably identified using two IHC markers, GATA3 and KRT5/6 [13, 39] . Similar correspondence between RNA-and IHC-profiling for the basal/squamous subtype was also obtained by others [41] . The literature therefore strongly indicates that luminal-like mRNA subtype(s) are robustly GATA3-positive on IHC, while non-luminal-like subtypes express low or no GATA3. In addition to low GATA3, the basal/squamous mRNA subtype is robustly identified by positive staining for KRT5 or KRT5/6. A straightforward classification that is concordant between mRNA and IHC levels, similar to that observed in breast cancer, would be highly desirable; however, remaining obstacles complicate direct comparison between transcriptional signature and IHC phenotype. First, there is variation in the content of immune and stromal cells both within and between tumor cell intrinsic subtypes. This is exemplified schematically in Figure 2 , where non-inflamed subtypes tend to have high sample purity, which results in tumor cell intrinsic subtype classification. Lum-papillary/UroA tumors show consistently low immune and stroma-signatures, which was confirmed by review of H&E slides [29] and by IHC for lymphocyte and myeloid cell markers [76] . In contrast, the basal/squamous subtype has a high immune signature and a high density of tumor-infiltrating immune cells [29, 76, 77] . This may be partly explained by differences in invasion depth, since the number of infiltrating lymphocytes correlates positively with tumor stage [78] . Furthermore, the process of sample taking itself plays a central role in the association between different TME types and tumor cell intrinsic subtypes. By sampling only isolated 570 G Sjödahl et al parts of tumors, systematic variation in sample purity is introduced. For example, research samples collected fresh from an exophytic tumor during trans-urethral resection of a bladder tumor (TURB-T) may have a different purity than routine pathology specimens from TURB-T or radical cystectomy specimens. Recently, Wang et al [79] demonstrated a positive correlation between stroma-and immune-related signatures in the TCGA RNA-seq data set. This correlation was no longer apparent after adjusting for tumor purity, suggesting that variation in purity and perhaps sampling cause immune-infiltrated tumors to also appear stroma-rich and vice versa. Despite attempts to control for tumor purity, e.g. excluding fresh tumor samples with purity lower than 50% [29] , or performing macro-dissection of tumor-rich area(s) before RNA extraction [14] , large gene expression studies consistently identify at least one large cluster of samples defined entirely by non-tumor intrinsic immune and/or stromal signals [14, 26, 29, 36] . It has been shown that these non-intrinsic mRNA subtypes, exemplified in the middle right panel in Figure 2 , can be resolved into the other intrinsic subtypes by in situ IHC analysis, but only partly by mRNA expression analysis [13, 14] . Finally, it is likely that both true TME type and considerations of purity and sample-taking methods will be relevant when subtypes of MIBC and NMIBC are to be reconciled. Untreated NMIBCs have fewer infiltrating non-tumor cells than MIBCs [76, 78] , but a low tumor burden may also result in samples of low purity. While these considerations may seem highly technical at first glance, they indicate that despite published claims to the contrary, 'infiltrated' transcript-based subtypes can be unreliable [13] . Non-infiltrated or in situ-based subtypes are likely to be more biologically meaningful and more useful in guiding clinical decision-making. An additional benefit of in situ profiling is the possibility of detecting intra-tumor heterogeneity, which cannot be resolved by transcriptomics. We currently do not know the proportion of bladder tumors that contain more than one molecular subtype and whether it is clinically meaningful. We also do not know if molecular subtypes depend on interactions with the microenvironment and to what extent they change in response to treatment, both of which are areas that require investigation. If we manage to validate the use of informative IHC assays on full TURB-T sections, future studies will be able to identify which cancers show subtype plasticity/heterogeneity and devise a management strategy based on their clinical behavior.
Envisioning molecular cell type profiling in routine pathology practice
If, as suggested by a wealth of work described above, UC subtype influences treatment outcomes, pathologists will need an efficient and effective method of assessing and reporting this information to clinicians who treat bladder cancer patients. Subtyping options to consider include whole transcriptome profiling, compact gene expression panels, and/or immunohistochemistry. To date, most studies have relied on large-scale transcriptomic (>40 000 probe) profiling to subtype UCs [25, 26, 28, 29, 36, 41] . This approach, while sometimes employed clinically [80] , suffers from a number of drawbacks. Because information from fewer than 100 genes is needed to make most clinical decisions [81] , assays may be unnecessarily complex, challenging to validate, computationally intensive, and ill-suited for deployment in local hospitals. Thus, they are typically available only as a sendout test. Sendout testing takes extra time and removes information gathering and interpretation from the local healthcare team, thereby compromising communication and storage of medical records and degrading the team's ability to interpret routine and atypical results and to employ them in research that can yield important biologic insights and improve patient care.
Compact gene expression panels such as Oncotype Dx and Mammaprint used for breast cancer typically incorporate fewer than 100 features [81, 82] . In contrast to whole transcriptome profiling, panels may be more widely adopted by local hospital laboratories, and perform better with small amounts of nucleic acid, allowing incorporation of diverse genomic features such as mutations, copy number variation, and gene expression into a single test. Indications for such testing currently focus on the presence of mutations (e.g. EGFR, BRAF) or fusions (e.g. ALK, ROS) that predict response or resistance (e.g. KRAS) to targeted therapies. Assays to measure expression of subtype-specific mRNAs could easily be incorporated into such panels to provide efficient testing for patients with UC. However, all of this information comes at a cost. Genomic testing or gene expression panels require expensive equipment and reagents, highly specialized personnel, and typically adds 1-2 weeks to the time required to complete a pathology report.
IHC has been a workhorse in surgical pathology laboratories for over 35 years. While challenging to use for quantitative purposes, IHC is routinely employed in cancer diagnosis for qualitative purposes, most commonly to query cell type differentiation. Thus, IHC is ideally suited for subtype determination. As an example of a clinically tractable scheme to employ IHC in subtyping, we suggest here an algorithm to be evaluated for IHC-based MIBC molecular subtype classification (Figure 3 ). With multiplexing, the vast majority of cases could be subtyped using one or two tissue sections using commercially available antibodies that are certified for use on routinely processed archival tissues [83] . We anticipate that UC subtyping will become established as a prognostic and predictive tool and propose the use of IHC for routine subtyping on diagnostic material from muscle-invasive cases. Molecular subtype will then be considered along with the entire clinical picture for each patient, including staging, renal function, comorbidities, and other information that influences choice of treatment. Once treatment options are enumerated, additional predictive tests can be tailored to these options and ordered on an as-needed basis. For the three major subclasses, which make up 87% of a consecutive cystectomy series [14] , no more than three antibodies should be required. As GATA3 is localized to the nucleus and KRT5 to the cytoplasm, the two are amenable to multiplexed assays, indicating that two tissue sections would suffice for sub-classification. (A) KRT5 and GATA3 expression yields three categories: Uro/GU (urothelial-like and genomically unstable subtypes), basal-SCCL (basal/SCC-like), and Mes-like/NE-like (mesenchymal-like and neuroendocrine-like). Basal SCCL requires no further testing. Rare tumors lack significant expression of both GATA3 and KRT5 and can be further sub-classified into Mes-like or NE-like subtypes. 
Summary/conclusion
Although molecular profiling has not yet formally shown clinical benefit in MIBC, the retrospective data on molecular subtypes and on biomarkers for targeted therapy are promising. The relationship between tumor microenvironment, sample purity, mRNA, and IHC-based profiling in MIBC is complex. The stability of molecular subtypes over time and the subtype heterogeneity within tumors and patients are yet unknown and strongly heterogeneous cases should be interpreted with caution. Molecular profiling by high-throughput RNA-based methods is possible, but IHC-based classification has the advantage of being readily available to any pathologist. We envision a world where subtyping is efficiently and effectively deployed to ensure (a) that patients derive maximal benefit from advances in clinical and translational research, and (b) that such prospectively collected information may feed back into research, providing a valuable resource for future discoveries.
